| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2015 | US20150057255 Use of nk-1 receptor antagonists in pruritus |
| 02/26/2015 | US20150057254 Once daily formulations of tetracyclines |
| 02/26/2015 | US20150057252 Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate |
| 02/26/2015 | US20150057250 Inhibitors of osteoclast activity for treating arthritis |
| 02/26/2015 | US20150057249 Vesicular Formulations |
| 02/26/2015 | US20150057246 Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| 02/26/2015 | US20150057244 Use of lipid conjugates in the treatment of disease |
| 02/26/2015 | US20150057242 Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis |
| 02/26/2015 | US20150057241 Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties |
| 02/26/2015 | US20150057239 Solid oral pharmaceutical compositions for isoxazoline compounds |
| 02/26/2015 | US20150057233 Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
| 02/26/2015 | US20150057226 Method for treatment of labor arrest |
| 02/26/2015 | US20150057221 Prodrug comprising a drug linker conjugate |
| 02/26/2015 | US20150057220 Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
| 02/26/2015 | US20150056451 Proton-binding polymers for oral administration |
| 02/26/2015 | US20150056314 Extraction method for use in extracting beneficial compounds from coffee beans |
| 02/26/2015 | US20150056308 Intranasal administration of ketamine to treat depression |
| 02/26/2015 | US20150056306 Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| 02/26/2015 | US20150056305 Dithiol mucolytic agents |
| 02/26/2015 | US20150056300 Therapeutic nanoparticles with high molecular weight copolymers |
| 02/26/2015 | US20150056299 Food supplement to support brain function |
| 02/26/2015 | US20150056298 Hepatic neuromodulation using fluids or chemical agents |
| 02/26/2015 | US20150056297 Nutraceutical combination for prevention and treatment of type 2 diabetes |
| 02/26/2015 | US20150056294 Methods and compositions for preparing a silk microsphere |
| 02/26/2015 | US20150056292 Joint Product Comprising Synephrine and Topiramate |
| 02/26/2015 | US20150056288 Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan |
| 02/26/2015 | US20150056287 Nanoparticulate megestrol formulations |
| 02/26/2015 | US20150056286 Nanoparticulate megestrol formulations |
| 02/26/2015 | US20150056284 Pharmaceutical composition |
| 02/26/2015 | US20150056281 Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta |
| 02/26/2015 | US20150056280 Isotopologues of 5-azacytidine |
| 02/26/2015 | US20150056279 Controlled Release and Taste Masking Oral Pharmaceutical Compositions |
| 02/26/2015 | US20150056278 Direct Compression Polymer Tablet Core |
| 02/26/2015 | US20150056277 Drug delivery system |
| 02/26/2015 | US20150056276 Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof |
| 02/26/2015 | US20150056275 Controlled-release solid dosage forms of mesalamine |
| 02/26/2015 | US20150056274 Compositions, methods and kits for reducing lipid levels |
| 02/26/2015 | US20150056270 Method for producing liposome encapsulating paclitaxel monoglycoside and/or docetaxel monoglycoside |
| 02/26/2015 | US20150056269 Liposome comprising at least one cholesterol derivative |
| 02/26/2015 | US20150056268 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| 02/26/2015 | US20150056267 Angiogenesis inhibitors |
| 02/26/2015 | US20150056255 Product Comprising a Plant for Medicinal, Cosmetic, Coloring or Dermatologic Use |
| 02/26/2015 | US20150056224 Compositions and methods for activating stimulator of interferon gene-dependent signalling |
| 02/26/2015 | US20150056221 Anti-prlr antibodies and uses thereof |
| 02/26/2015 | US20150056217 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4 associated disorders |
| 02/26/2015 | US20150056215 Methods of treating proliferative disorders with malate or derivatives thereof |
| 02/26/2015 | US20150056213 Selective histone deactylase 6 inhibitors |
| 02/26/2015 | US20150056207 Combination therapy with c-met and egfr antagonists |
| 02/26/2015 | US20150056195 Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy |
| 02/26/2015 | US20150056193 Egfr and ros1 kinase in cancer |
| 02/26/2015 | US20150056192 Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
| 02/26/2015 | US20150056191 Igf1 biomarker for igf1r inhibitor therapy |
| 02/26/2015 | US20150056186 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 02/26/2015 | US20150056178 Modified beta-lactamases and methods and uses related thereto |
| 02/26/2015 | US20150056176 Anti-inflammatory composition |
| 02/26/2015 | US20150056166 Flavone derivatives and their use |
| 02/26/2015 | US20150056164 Antiviral Compounds and Uses Thereof |
| 02/26/2015 | US20150056163 Leukotoxin e/d as a new anti-inflammatory agent and microbicide |
| 02/26/2015 | US20150056160 Chemically induced intracellular hyperthermia |
| 02/26/2015 | US20150056157 Vascular delivery systems |
| 02/26/2015 | US20150056149 Topical tetracycline compositions |
| 02/26/2015 | US20150056147 Abuse-proofed dosage form |
| 02/26/2015 | US20150056144 Encapsulated diagnostics and therapeutics in nanoparticles - conjugated to tropic cells and methods for their use |
| 02/26/2015 | US20150056140 Electrolyte purgatives |
| 02/26/2015 | US20150056135 Treatment of Proliferative Disorders Using Antibodies to PSMA |
| 02/26/2015 | DE112013002717T5 Induktion von Arteriogenese mit einem NO (Stickstoffmonoxid)-Donor Induction of arteriogenesis with an NO (nitric oxide) donor |
| 02/26/2015 | DE102013013986A1 Zusammensetzung mit Kühlwirkung für die topische Anwendung Composition with cooling effect for topical application |
| 02/25/2015 | EP2840083A1 Nitrogenated bicyclic aromatic heterocyclic compound |
| 02/25/2015 | EP2840081A1 Use of a novel aminopyridine derivative to prevent or treat cancer |
| 02/25/2015 | EP2840080A1 Nitrogen-containing heterocyclic compound or salt thereof |
| 02/25/2015 | EP2840076A1 Bicyclic compound |
| 02/25/2015 | EP2839835A1 Encapsulated formulation |
| 02/25/2015 | EP2839834A1 Dermatological composition comprising plant stem cells and a derivate of salicylic acid |
| 02/25/2015 | EP2839833A1 Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of the topical pharmaceutical composition and method for the topical treatment of psoriasis, atopic dermatitis or chronic eczema |
| 02/25/2015 | EP2839832A2 Use of dipeptidyl peptidase IV inhibitors |
| 02/25/2015 | EP2839831A1 Modulators of the unconventional secretory pathway for use in the treatment of Alexander disease |
| 02/25/2015 | EP2839830A1 Kits and compositions for treating lower urinary tract disorders |
| 02/25/2015 | EP2839829A1 Sustained release tablet containing levodropropizine and method for preparing same |
| 02/25/2015 | EP2839828A1 Compunds and formulations for the treatment of wounds |
| 02/25/2015 | EP2839004A1 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| 02/25/2015 | EP2838907A2 Aminosteroids for the treatment of a ptp1b associated disease |
| 02/25/2015 | EP2838906A1 Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
| 02/25/2015 | EP2838903A1 Methods and compositions for treating viral infections |
| 02/25/2015 | EP2838902A1 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| 02/25/2015 | EP2838901A1 6- (4- (1 -amino- 3 -hydroxycyclobutyl) phenyl) - 5 - phenyl (furo, thieno or pyrrolo) [2, 3-d]pyrimidin- 4 - one derivatives for the treatment of cancer |
| 02/25/2015 | EP2838899A1 Thiazolidinedione derivatives, preparation thereof and use thereof in cancer treatment |
| 02/25/2015 | EP2838898A1 Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| 02/25/2015 | EP2838895A1 Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| 02/25/2015 | EP2838892A1 Methods of producing anamorelin hydrochloride having controlled chloride content |
| 02/25/2015 | EP2838891A1 Aromatic ring compound |
| 02/25/2015 | EP2838890A1 Fluorinated benzofuran derivatives |
| 02/25/2015 | EP2838889A2 Lichesterinic acid and the derivatives of same as pigmentation inhibitors |
| 02/25/2015 | EP2838888A1 Thiadiazolidinediones as gsk-3 inhibitors |
| 02/25/2015 | EP2838887A1 (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| 02/25/2015 | EP2838884A1 Geranyl geranyl acetone analogs and uses thereof |
| 02/25/2015 | EP2838883A1 New phenyl-tetrahydroisoquinoline derivatives |
| 02/25/2015 | EP2838882A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 02/25/2015 | EP2838881A1 Isoindolone derivatives |
| 02/25/2015 | EP2838879A1 Deuterated rigosertib |
| 02/25/2015 | EP2838569A1 Optimizing ungual treatment by quantitative autoradiography |